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ABSTRACT
Smce the introduction of oral contraceptives, their use has been associated with
an increased risk of both venous and arterial thrombosis. Pulmonary embolism, myocar-
dial infarction, and stroke are serious disorders with a considerable risk of mortality. Be-
cause worldwide over 100 million women use oral contraceptives, issues of drug safety are
of great importance. The risk of venous thrombosis during low-dose oral contraceptive
use is three- to sixfold increased compared with that of nonusers. The association is not
only attnbuted to the estrogen component of the pill: the risk is twice äs high for desogestrel
and gestodene (third generation) containing oral contraceptives äs for levonorgestrel (sec-
ond generation) containing oral contraceptives. The risk of venous thrombosis is highest
in the first year of use and in women with genetic or acquired risk factors for thrombosis.
Both venous or arterial thrombosis are unrelated to duration of use or past use of com-
bined oral contraceptives. The risk of myocardial infarction and stroke during low-dose
oral contraceptive use is two- to fivefold increased relative to that of nonusers. The risk of
arterial thrombosis induced by oral contraceptive use is more pronounced m smokers and
women with hypertension, diabetes, and hypercholesterolemia. All types of thrombosis
have strongly age-dependent incidences, and therefore in absolute figures the risks and
effects of risk factors increase with age. The lowering of the estrogen dose in combmed
oral contraceptives from 50 pg to 20—30 μg in the last decade did not clearly reduce the
risk of venous thrombosis, myocardial infarction, stroke, or peripheral arterial disease. For
stroke and peripheral arterial disease no difference in risk was found between second and
third generation oral contraceptives. For myocardial infarction study results are conflict-
ing, and a small benefit of third- over second-generation oral contraceptives cannot be
ruled out. However, this is unlikely to counterbalance the adverse effect of third genera-
tion contraceptives on venous thrombosis.
KEYWORDS: Oral contraceptives, estrogens, progestagens, venous thrombosis,
arterial thrombosis, epidemiology
Educational Objectives: Upon completion of this article, the reader will be able to (1) summanze the most important determmants
of venous and arterial thrombosis, and ascertain whether a putative interaction with oral contraceptive use is present (2) compre-
hend the latest developments in understandmg the possible mechanisms underlymg an increased thrombotic risk for both venous
and arterial thrombosis by oral contraceptive use, and (3) explam how second and third generation oral contraceptives differ from
each other m influencmg coagulation and lipid levels
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l hrombosis, venous äs well äs arterial, is the most
frequently occurring serious side effect of combined oral
contraceptives (OCs). Millions of women all over the
world use OCs for many years and therefore side effects
are highly relevant. Even a small increase in risk will lead
to disease in a large number of women who are often
healthy and young. Most women use OCs äs a method
for birth control; OCs are more rarely used for other
reasons such äs acne and dysmenorrhea.
For almost 40 years it has been known that OC
use is associated with an increased risk of cardiovascular
disease. A boost in understanding the pathogenesis of
venous thrombosis came when we became aware of the
gene-environment interaction in which OC use coinci-
dences with heritable clotting defects leading to a dis-
balance of hemostatic factors.The identification of new
risk factors (apart from the classical ones, i.e., deficiency
of antithrombin, protein C, or protein S) for venous
thrombosis, that is, factor V"Lci[ien) prothrombin 20210A,
high levels of factor ΥΊΙΙ, IX, and XI, thrombin-activat-
able fibrinolysis inhibitor (TAFI), and hyperhomocys-
teinemia, has greatly improved insight into the etiology
of venous thrombosis and especially resistance to acti-
vated protein C (APC resistance) in the understanding
oftheroleofOCs.1
For arterial thrombosis, however, the role of hemo-
static risk factors is less clear.2 Although numerous studies
have been published on the role of genetic risk factors for
myocardial infarction, studies are limited by their sample
size, which was mostly insufflcient to establish the risk of
a single polymorphism in a complex disease.3·4
Thrombosis is a multicausal disease in which ac-
quired and genetic causes interact.5 The effects of OCs
on venous thrombosis, myocardial infarction, and is-
chemic and hemorrhagic stroke are strongly influenced
by other risk factors for thrombosis, which are different
for venous and arterial thrombosis. Venous thrombosis
is an acute event in contrast to most types of arterial
thrombosis, which predominantly occurs in vessels with
preexistent atherosclerotic disease. Table l summarizes
the main risk factors for both types of thrombosis.
In this article, we evaluate the epidemiology of
venous and arterial thrombosis during OC use. We re-
strict ourselves predominantly to the studies of com-
bined OCs from the last decade and give a summary of
the studies that also focus on differences between OCs,
that is, the dose of estrogen and the different types of
progestagens.
COMPOSITION AND MODE OF ACTION
OF ORAL CONTRACEPTIVES
Most OCs contain an estrogen and a progestagen
(monophasic preparations). In biphasic and triphasic
combinations, the content of the pills during one cycle
varies, with more estrogen in the early phase of the cycle
and more progestagen in the later phase of the cycle. OCs
act by preventing ovulation through the action of prog-
estagen, which suppresses luteinizing hormone. Some for-
mulations contain only a progestagen, and these cause a
higher frequency of breakthrough bleedings. The major
role for the estrogen component in the pill is to prevent
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*These genetic defects are clear risk factors for venous thrombosis, their role m arterial disease is less clear and much less pronounced
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breakthrough bleeding and spotting by organizing the
endometrium. With optimal compliance the failure rate
is less than 1%.
During the past four decades the hormonal con-
tents of combined OCs have changed. The estrogen dose
has been reduced from 150 μg mestranol or ethinyl-
estradiol to 20-30 μg ethinylestradiol, the so-called low-
dose formulations. Ethinylestradiol is a synthetic estra-
diol, which is active when metabolized in the liver.
Progestagens are grouped into "generations" based
historically on when they were first produced because of
the absence of a formal classification System. OCs from
the 1960s contained a first-generation progesteron (nore-
thisterone, lynestrenol), and from the 1970s onward the
second generation (levonorgestrel, norgestrel, norgestri-
one) was used. To minimize the androgenic side effects
third-generation progestagens (desogestrel, gestodene)
have been developed, and these have been used from the
early 1980s in Europe and since the 1990s in the United
States. Norgestimate, also marketed since the 1980s, is
partly metabolized into levonorgestrel, so it cannot be
readily categorized. In this System of generations, cypro-
terone acetate and drosperinone are not classified.
ASSOCIATION BETWEEN ORAL
COIMTRACEPTIVES AND THROMBOSIS
The clinical observations linking OC use with venous
thombosis,6 ischemic stroke,7 and myocardial infarc-
tion8 were made shortly after their introduction in the
early 1960s, including fatal cases from thromboembolic
disease. In subsequent studies the death rate from all types
of cardiovascular events during OC use appeared to be
five times that of control women who had never used
OCs, and the risk did not differ between the older for-
mulations with high (s 50 μg) estrogen dose and the
newer low-dose (< 50 μg) OCs from the 1970s.9·10 If the
risk went down over the years, it may have been the re-
sult of more careful prescription of OCs.11
Age is an important risk factor for thrombosis.
Thrombosis rarely occurs before puberty, after which the
annual incidence progessively increases. Incidences of
cardiovascular disease and mortality data during the re-
productive age are summarized in Table 2. Until age 40,
venous thrombosis is the most common form of throm-
bosis with a low mortality. After age 30, however, mor-
tality is higher for arterial than for venous thrombosis
and increases exponentially through the reproductive age
pcriods. Today, women tend to start OC use earlier and
use them for a longer period.12
Venous Thrombosis
Venous thrombosis occurs most offen äs deep vein throm-
bosis of the leg and pulmonary embolism. Although only
10% of patients with deep vein thrombosis have symp-
Table 2 Incidence of VenousThromboembolism,
Myocardial Infarction, and Ischemic Stroke and
Incidence of Death atYoung Age178
































toms indicative of pulmonary embolism, half of the pa-
tients have unequivocal evidence of asymptomatic pul-
monary emboli.13·14 Mortality is higher for pulmonary
embolism than for deep vein thrombosis because the di-
agnosis can be easily missed in previously healthy women.
Relative risks for fatal pulmonary embolism associated
with OC use were found to be the same for older for-
mulations and currently available combined OCs.15·16
The first case-control study on venous thrombo-
sis reported a threefold increased risk in OC users com-
pared with nonusers,17 which was soon confirmed by
other studies. 18~"21 In the early 1970s estrogens were found
to be responsible for the increased risk of thrombosis,22
but certain discrepancies in the data already suggested
that the dose of estrogen could not be the only factor re-
lated to the risk of thrombosis.23
ESTROGENSAND PROGESTAGENS
Studies performed between 1967 and 1993 did not show
a substantial risk reduction for venous thrombosis de-
spite the lowering of the estrogen dose in the 1970s and
the introduction of new progestagens in the 1980s.24·25
The newest progestagens (so-called third generation
progestagens) were introduced after studies with inter-
mediate endpoints in young healthy women (e.g., blood
pressure, lipid and glucose levels, and various coagu-
lation and fibrinolysis parameters).26 Although third-
generation progestagens seemed to influence lipid and
carbohydrate metabolism less than the older formula-
tions, adverse side effects on the hemostatic System have
been underestimated. Despite some reports of severe
thrombogenic episodes and fatal pulmonary embolism
during third-generation OC use,27·28 only a few studies
reported on hemostatic adverse effects in depth.29 This
was probably due to the absence of knowledge of which
parameters were important, and it lasted 25 years before
the effect of progestagens on clotting was recognized.
Unexpectedly, therefore, in 1995 and 1996, a further two-
fold increased risk of venous thrombosis was reported in
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several studies including OCs containing desogestrel and
gestodene (third generation) compared with OCs with
previous generations of progestagens.30"33 Subsequent
studies confirmed these fmdings and also showed a higher
risk of fatal pulmonary embolism during third-generation
OC use.16-34
A recent meta-analysis of the risk of third-genera-
tion OCs and the risk of venous thrombosis showed an
overall adjusted odds ratio of 1.7 (95% confidence inter-
val [CI] 1.4-2.0) relative to the use of second-generation
OCs.35 In a subgroup analysis, the odds ratlos differed
between studies sponsored by the pharmaceutical indus-
try (OR 1.3; 95% CI 1.0-1.7) and non-industry-spon-
sored studies (OR 2.3; 95% CI 1.7-3.2), according to an
earlier comment on the influence of competing interest.36
After the medical alert in 1995, changes have occurred in
OC prescriptions according to recommendations from
health authorities.37'38 Consistency of the study results
thereafter, reasonable certainty about the absence of bias
äs well äs confounding, and a remarkable start in under-
standing biological plausibility may contribute to the ap-
preciation of a causal relationship between third-genera-
tion OCs and venous thrombosis.39"48
MAGNITUDE OF RISK OF VENOUS THROMBOSIS
Women who take low-dose OCs still have a risk of ve-
nous thrombosis that is increased three- to sixfold com-
pared with that of nonusers.49~51 The majority of women
who use OCs remain free of thrombotic events, but in
combination with other acquired risk factors and partic-
ularly in women with genetic thrombophilic defects OC
use will often trigger thrombosis.52"56
The absolute risk of venous thrombosis among
OC users has been estimated at 2.0 and 3.0 per 10,000
users per year,46·52 compared with 0.8 per 10,000 per
year in nonusers.52 Given the steep age dependence of
the thrombosis incidence, absolute risks are consider-
ably lower in the youngest and considerably higher in
the older users. For venous thrombosis, the risk is high-
est in the first 6 months of OC use.S7This does not in-
dicate an effect of duration but risk stratification between
users: those with a high "thrombotic potential" (for in-
stance, due to prothrombotic mutations) will develop
thrombosis shortly after being exposed to an additional
risk factor such äs OCs. Analogous results have been
found for postmenopausal hormones and myocardial
infarction.58
The case-fatality rate for venous thromboembolism
is slightly lower than for arterial diseases and is assumed
to be about 2-5%.59'60 Workers from New Zealand re-
ported seven cases of women who used third-generation
OCs and died from pulmonary embolism.16 The ab-
solute risk of fatal pulmonary embolism in this study
was estimated to be 10 per million women-years.
Duration of OC use does not effect the risk esti-
mates of venous thrombosis, nor does lifetime duration
of use.42·49 The risk increase disappears within 3 months
after stopping OCs; that is, the risk is immediate, re-
versible, and does not accumulate.
UNCOMMON FORMS OFVENOUS THROMBOSIS
A strong association has been found between cerebral
sinus thrombosis and OC use and in synergy with factor
^Leiden and prothrombin 20210A.61~64 The increased
risk for third-generation OCs compared with other OCs
was also found for cerebral venous sinus thrombosis.65
Several case reports have highlighted the association be-
tween retinal vein occlusion and OCs,66·67 but in a pop-
ulation-based study this association has not been con-
firmed.68 OC use has been associated with Budd-Chiari
syndrome in case reports.69'70 In a multicenter case-control
study, Budd-Chiari syndrome and portal vein thrombo-
sis were found to be multicausal diseases. In a third of
these patients concurrent acquired or genetic risk fac-
tors for thrombosis were present, but OCs were not
found to be an important risk factor.71
The post-thrombotic syndrome is a chronic con-
sequence of deep venous thrombosis that has received
little attention to date. Few studies have looked at the re-
lation with OC use.72 This syndrome occurs in almost
30-60% of the patients with deep venous thrombosis
and is strongly related to ipsilateral recurrent deep ve-
nous thrombosis but is not directly related to the extent
of the thrombosis.13 Superficial thrombophlebitis has
also been associated with OC use in older reports but in
recent studies failed to be significant.73
Arterial Thrombosis
Myocardial infarction and ischemic stroke are due to cell
necrosis after reduced blood flow related to occlusion of
one or more coronary arteries in the case of myocardial
infarction or occlusion of the intracranial or extracranial
arteries in the case of ischemic stroke. Hemorrhagic
stroke is caused by an arterial rupture. Spasm or dissec-
tion of the blood vessels has also been associated with
endogenous (pregnancy, puerperium) and exogenous sex
hormones. Coronary thrombosis is usually precipitated
by endothelial denudation or plaque fissuring or rupture.
Occluding thrombi often occur at sites with angiograph-
ically minimal or absent underlying Stenosis. Patients
with cerebral thrombosis present with clinical Symptoms
reflecting the size and location of the artery involved.
Large artery occlusions may present in a sudden or grad-
ual or stepwise fashion, with or without a prior transient
ischemic attack. Thrombosis without underlying athero-
sclerotic disease may occur in patients with coagulation
disorders, especially in young patients without conven-
tional stroke risk factors and with recurrent unexplained
episodes of thrombosis.74
Peripheral arterial occlusive disease is rare in young
women but carries a poor prognosis with a high incidence
of vascular graft occlusion and amputation and therefore
high morbidity.75'76 In older reports, a causative relation-
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ship between early localized arteriosclerosis in the distal
aorta in women of reproductive age with intermittent
claudication and long-term OC use has been suggested,77
for example, mesenterial thrombosis,78 and thrombosis
of the digital vessels.79 There are no studies available on
the association between OC use and these rare manifes-
tations of arterial thrombosis, which may simply reflect
their low incidence.
Myocardial Infarction
The introduction of newer low-dose OCs over time has
coincidenced with a reduction in the incidence of myo-
cardial infarction.80 This may point to lower thrombo-
genicity of these OCs but could also be explained by
secular trends in the post—World War II epidemic of
cardiovascular disease. In the MONICA study, the esti-
mated incidence rates ranged from 0 to 3 per 100,000
women-years in the age group 25-34 years and 6 to 14
per 100,000 women-years in the age group 35-44 years.81
Mortality from myocardial infarction is low, < 0.4 per
100,000 women-years at age 15-24 and 2-7 per 100,000
women-years at age 35-44 years. In the United States
similar risks were found, 1-2 per 100,000 women-years
in women younger than 35 years, 4.1 per 100,000 women-
years in women aged 35—39 years, and 10—21 per 100,000
women-years for women in their 40s. Most of the risk is
confined to women with additional risk factors such äs
smoking, hypertension, diabetes, hyperlipidemia, and obe-
sity. Estimates of fatality rates for myocardial infarction
differed between studies, countries, and age groups be-
tween 8 and 50%. The 28-day case-fatality rate in women
aged 15-44 years was between 20 and 30%.60
RISK AND RISK FACTORS
Among the studies on the association between myocar-
dial infarction and OCs, few data are available on the
currently used low-dose OCs. More recent studies showed
a small increased risk for nonsmoking OC users but still
a high risk for smokers.82~84The results of the five stud-
ies on first myocardial infarction and low-dose OCs are
summarized in Table 3.82>83>85~87 Myocardial infarction
was defmed by electrocardiographic changes, increased
cardiac enzymes, and the presence of ehest pain. The
overall estimated risk associated with low-dose OC use
is a twofold increase. In Europe, but not in developing
countries, relative risks associated with estrogen dose
did not differ between higher and low-dose OCs. Among
women who used OCs and had additional risk factors,
the risk of myocardial infarction increased to 6-fold for
hypertensive OC users, 13-fold for smoking OC users,
17-fold for diabetic OC users, and 24-fold for hyper-
cholesterolemic OC users.87
Five studies have been published that presented a
direct comparison of third- and second-generation OCs
in relation to the risk of myocardial infarction. These
studies were heterogeneous with respect to case and con-
trol selection äs well äs to the outcome. Overall there
was a slight but not significant lower risk of myocardial
infarction for third- compared with second-generation
OCs (Table 4). The World Health Organization (WHO)
study, however, found no difference in risk between sec-
ond- and third-generation OCs in women who have had
a blood pressure check.85 In a recent study the risk of
death within l month after myocardial infarction was
increased for second-generation OCs compared with no
use (OR 2.9; 95% CI 1.2-6.8) but not for other types of
Table 3 Adjusted Odds Ratios for Myocardial Infarction in Current Oral Contraceptive
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4 8 (2 5-9 1 )
77 (33-180)
29(1 2-70)
5 0 (2 5-9 9)
4 5 (2 0-100)
4 7 (2 0-10 9)
2 4 (1 4-3 9)
0 9 (0 4-2 2)
1 4 (0 8-2 5)
2 1 (1 5-3 1)
2 0 (06-73)*
2 6 ( 1 6-4 2)*
"Analyses were restncted to OCs with 50 pg ethmylestradiol (EE) and 125 pg levonorgestrel and OCs with
30 pg ethmylestradiol and 150 pg levonorgestrel
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Table 4 Relative Risk of Myocardial Infarction in Current Users of Low-Dose (<50|xg of Estrogen) Combined Oral
Contraceptives Containing DifferentTypes of Progestagen, Compared with Nonusers or Users of Low-Dose
Combined Oral Contraceptives Containing Levonorgestrel
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*ln women with a blood pressure check prior to prescription, odds ratios were 1 0 for second and third generation oral Contraceptives
Contraceptives.88 However, this conclusion was based on
only 3 deceased patients and 17 patients who stayed
alive after myocardial infarction.
Duration of OC use has not been proved to be
important in the relation to the risk of myocardial in-
farction,59·85 and no evidence was found that long dura-
tion of OCs adversely affects long-term risk of mortal-
ity due to myocardial infarction.89
Lack of an effect of past use of OCs for coronary
disease is well documented,90 and more recent studies
also failed to show an increased risk among past users of
OCs.84·85-91·92
It has been hypothesized that myocardial infarc-
tion during OC use is a separate disease entity, äs com-
pletely normal coronary angiographies have been found
in women with thrombotic coronary occlusions.93'94This
suggests that the effect of OCs, also on arterial disease,
is thrombotic rather than atherogenic and is in accor-
dance with an immediate, reversible, noncumulative ef-
fect. If this hypothesis is true, the theoretically benefi-
cial effect of the third generation on the lipid profile may
not lead to a lower risk of myocardial infarction. In ad-
dition to OCs, smoking cigarettes is particularly a risk
factor for acute coronary thrombosis in women.95
Stroke
The incidence of fatal ischemic and hemorrhagic stroke
is very low in women of reproductive age but increases
exponentially with age.96 In the MONICA project the
incidence of ischemic stroke was 73.1 per 100,000 women
aged 15 to 55 years.97 Incidence of ischemic stroke was
estimated between 4.1 and 11.3 per 100,000 women-
years in women between 15 and 44 years of age in a
population from the United States.98"100 Case-fatality rates
for stroke differed in different studies but have been re-
duced in recent years to 5-20% of ischemic strokes.
RISK OF ISCHEMIC STROKE
In studies before 1990 combined OCs were found to be
associated with a three- to fourfold increased risk of first
ischemic stroke.101"103 The results of the eight recent
studies on ischemic stroke are summarized in Table 5.
Stroke was defmed by the presence of specific symp-
toms and the results of imaging procedures.Current use
of low-dose combined OCs is still associated with is-
chemic stroke with relative risk estimates varying from
1.2 to 3.1.98,104-107 Migraine, particularly with aura, dur-
ing OC use has been described a.s an additional risk fac-
tor for ischemic stroke.108'109
Four studies investigated the risk of ischemic stroke
according to progestagen type; these studies are sum-
marized in Table 6. The overall odds ratios were quite
similar and no differences between second- and third-
generation OCs were found.
The risk of stroke among past users of OCs was
not increased in the majority of the studies.98·106 In both
older15·20·102'110 and recent studies, duration of OC use
was without influence on the risk of stroke and the odds
ratios were constant over the age bands.106 Increased risk
in long-term (> 6 years) users has been found but can
also be related to OC-induced hypertension.104 A seem-
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3 0 ( 1 7-5 4)
53(26-110)
1 5 (0 7-3 3)
2 9 (2 2-4 0)
2 7 (1 8-4 2}
3 3 (2 2-4 9)
1 2 (0 5-2 6)
1 1 (0 6-2 2)
0 9 (0 3-2 9)
3 6 (2 4-5 4)
2 7 ( 1 1-63)
1 6(1 1-24)
1 6 (0 6-4 6)
2 1 (1 5-3 1)
2 3 (0 6-9 0)f
24(14-4 1)t
*No confidence mtervals were provided m the original paper
fAnalyses were restricted to OCs with 50 pg ethmylestradiol (EE) and 125 pg levonorgestrel and OCs with
30 pg ethinylestradiol and 150 pg levonorgestrel
ingly similar but different observation was made in rela-
tion to recency of use.
RISK OF HEMORRHAGIC STROKE
The risk of hemorrhagic stroke associated with OC use
is less well established than that of ischemic stroke. The
Overall relative risk for hemorrhagic stroke associated
with OCs from three recent studies was estimated to be
1.5-fold (95% CI 1.1-1.9) increased compared with that
of nonusers98·100'111 but increased substantially in ciga-
rettes smokers (3-fold) and in women with hyperten-
sion (10- tol5-fold).98>m The risk of hemorrhagic stroke
in OC users was not elevated in women younger than
35 years, but in women older than 35 it was estimated to
be elevated 2.2-fold compared with that of nonusers.
Smoking increased the risk further.60 For hemorrhagic
stroke there is no evidence that there is a difference in
risk between second- and third-generation OCs.107·112
Peripheral Arterial Occlusive Disease
A unique pattern of localized aortoiliac atherosclerosis
in the distal aorta in young women with intra-arterial
thromboembolic events at presentation has been de-
scribed, but the role of OCs in premature arteriosclero-
sis has not been investigated.75'77 In an animal model,
however, no increase of arterial thrombosis was found
after 30 months of OC treatment.113
In a population-based case-control study among
young women all types of OC use were associated with
a 3.8-fold risk (95% CI 2.4-5.8) of peripheral arterial
disease. There was no difference in risk between 50 and
30 μg ethinylestradiol-containing combined contracep-
tives or between second- and third-generation OCs.114
The odds ratio for second-generation OCs was 2.6 (95%
CI 1.4-4.9) and for third-generation OCs was 3.0 (95%
CI 1.4-6.6).
INTERACTION WITH OTHER RISK
FACTORS DURING ORAL
CONTRACEPTIVE USE
A positive interaction between cigarette smoking and
current OC use with high risks of myocardial infarction
was already recognized m the 1970s.115 Several studies
confirmed a higher risk than expected for myocardial
infarction in OC users who smoked in comparison with
nonsmokers for both high-dose and low-dose formula-
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Table 6 Relative Risk of Ischemic Stroke in Current Users of Low-Dose (<50 μ9 of Estrogen) Combined Oral
Contraceptives Containing DifferentTypes of Progestagen, Compared with IMonusers or Users of Low-Dose

































































*Direct comparison between 30 μ9 ethinyestradiol-containing formulations only.
tions.85'87·116 Smoking is by far the most important risk
factor for the occurrence of arterial cardiovascular dis-
ease in young women.117 For myocardial infarction the
relative risks ranged from 11- to 22-fold, and higher risks
were found with increasing number of cigarettes.85~87 For
ischemic stroke the relative risk ranged from 4 to 7 äs
compared with nonusers who did not smoke.104
OCs are a risk factor for myocardial infarction
especially when there are other cardiovascular risk fac-
tors, that is, hypertension, diabetes, hypercholesterolemia,
and obesity, and these risk factors increase with age.118·119
As the absolute risk of myocardial infarction is highly
age dependent, OCs will have the most impact in older
women. Unfortunately, in many studies of the associa-
tion between OCs and cardiovascular disease, patients
with conventional risk factors have been excluded, re-
sulting in a lack of data on combinations of risk factors.
In contrast to the progress that has been made in
understanding the genetic contributions to venous throm-
bosis, much still remains to be studied on the genetic
base of arterial thrombosis. A major complication in the
study of gene-environment interaction for arterial dis-
ease is that this has a chronic process of atherosclerosis
compounded by an acute thrombotic event, in contrast
to venous thrombosis, which is due to acute clot forma-
tion. Despite the documentation of associations between
several genetic polymorphisms and plasma coagulation
factor levels, consistent associations with arterial throm-
botic disease have not been found.3·4
The influence of genetic defects on myocardial
infarction and stroke has been investigated since 1995
with varying outcomes. Different results on the contri-
bution of genetic defects seem to depend on the type of
population that has been studied. Positive associations
between prothrombotic mutations (i.e., factor VL idcn,
prothrombin 20210A) and the risk of myocardial in-
farction were found among young women, particularly
smokers and women with other cardiovascular risk fac-
tors120'121 or patients with normal angiographies.74 The
risk of myocardial infarction was similar among women
who used OCs whether or not they had a prothrombotic
mutation.87 Data on the effect of prothrombotic muta-
tions and stroke are controversial. Most studies in women
did not find an increased risk of stroke in the presence
of prothrombotic mutations.122'123
EFFECTS OF ORAL CONTRACEPTIVES ON
THE COAGULATION SYSTEM
Changes of Coagulation Factors
Elevations of the procoagulant factors fibrinogen, pro-
thrombin, and factors VII, IX, X, and XII and decrease
of the anticoagulant factors protein S and antithrombin
are consistent effects of OCs on the hemostatic sys-
tem.124~126 Women differ in the extent of these changes,
and it has been suggested that so-called high responders
have the highest risk.127 The underlying mechanisms of
this response are unknown. Upon cessation, coagulation
parameters returned to normal within 3 months.128
Acquired Activated Protein C Resistance
APC resistance is defined äs an impaired plasma antico-
agulant response to APC in vitro. After the discovery of
inherited poor anticoagulant response to APC äs a risk
factor for familial venous thrombosis,129 factor V, . ,' Leiden
was found äs the most common cause of inherited APC
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resistance.130·131 Factor V. , is caused by a single baseLeiden J o
mutation (G1691—»A) in the factor V gene resulting in
the replacement of Arg506 by Gin at the predominant
cleavage site for APC. Besides inherited APC resistance,
other coagulation disorders are associated with APC re-
sistance, that is, antiphospholipid antibodies and ele-
vated factor VIII levels. Acquired APC resistance with-
out the presence of factor VLeidcn was recognized in OC
users132"137 and is one of the major epidemiologic obser-
vations explaining the increased risk in OC users.1·138>139
It is more pronounced in women using third-generation
OCs than in second-generation OC users.140"143 Acquired
APC resistance is best measured with a APC sensitivity
assay based on the endogenous thrombin potential (ETP),
in which coagulation is initiated through the extrinsic
pathway, which proved to be more sensitive to exoge-
nous factors than the commonly used activated partial
thromboplastin time (aPTT)—based test.144 Women who
used third-generation OCs had almost the same degree
of APC resistance äs carriers of factor VT , withoutbeiden
OC use.145 In addition, women with APC resistance re-
lated to factor VLciden are most susceptible to acquired
APC resistance associated with OC use, probably due
to a gene-environment interaction. Moreover, a dose-
response relationship between the severity of APC re-
sistance and the risk of venous thrombosis has been ob-
served with a fourfold increased risk for values in the lower
quartile compared with those in the highest quartile.146
Acquired Decreased Levels of Protein S
and Antithrombin
During OC use protein S and antithrombin levels de-
crease.53'125·147 Women with inherited antithrombin de-
ficiency developed venous thrombosis during OC use or
pregnancies earlier in life than women with inherited
protein S deficiency.148Antithrombin levels decrease more
with gestodene-containing OCs than with levonorgestrel-
containing contraceptives.149·150 In a randomized con-
trolled trial both free and total protein S in plasma from
users of desogestrel-containing OCs were more decreased
than in plasma from users of levonorgestrel-containing
OCs.143
cardiovascular risk,153 possibly in particular to the risk
of arterial disease. Pvise of fibrinogen was dependent on
estrogen dose and Smoking.
EFFECTS OF ORAL CONTRACEPTIVES ON
THE CARBOHYDRATE AND LIPID SYSTEM
OCs can induce substantial changes in plasma glucose and
lipoprotein levels similar to those associated with an in-
creased risk of cardiovascular disease, including increased
levels of glucose and insulin, increased levels of triglyc-
erides and low-density lipoprotein (LDL), decreased levels
of high-density lipoprotein (HDL),154 and increases in
systolic and diastolic blood pressure.116 GeneraUy, all low-
dose combined OCs produce a slight increase in insulin re-
sistance and a decrease in glucose tolerance. Modifications
in lipoprotein parameters may depend on the estrogen or
progestagen content of each formulation.155 In most com-
parative studies these changes were moderate and reported
äs staying within normal limits.156"159
PROGESTAGEN-ONLY FORMULATIONS
Progestagen-only contraceptives are used by only a small
percentage of women. In the past, progestagen-only
preparations have been used by women for whom com-
bined OCs were contraindicated. Changes in lipid para-
meters have been observed with progestagen-only prepa-
rations, which showed a decrease in total cholesterol,
HDL cholesterol, and triglycerides. Changes in LDL
cholesterol were dependent on the type of progestagen;
an increase was found with levonorgestrel-only and a de-
crease with desogestrel-only preparations.160 The WHO
Collaborative Studyof Cardiovascular Disease and Steroid
Hormone Contraception found no increased risk of myo-
cardial infarction and stroke and an unclear effect with
regard to venous thromboembolism.161 However, among
women with hypertension, progestogen-only contracep-
tives increased the risk of stroke. In a more recent study
there was no effect on venous thrombosis with progesta-
gens alone used for contraception,162 but a substantial
association has been found with higher dose progesta-
gens for other indications, that is, menstrual disorders.163
Fibrinolytic Factors
OCs induce changes in fibrinolytic parameters, but
changes in the fibrinolytic system have not been associ-
ated with venous thrombosis. High levels of TAFI have
been found to be a mild risk factor for venous thrombo-
sis.151 TAFI levels increase during OC use, inducing a
hypofibrinolytic state, which is more pronounced with
third- than with second-generation OCs.1S2This can be
one of the mcchanisms by which OCs contribute to the
thrombotic risk.
Fibrinogen increases considerably by 10 to 20%
during OC use, which may contribute to the increased
CLINICAL RECOMMENDATIONS
Screening
Routine screening of all women for genetic risk factors
before prescription of an OC is not cost effective. In ad-
dition, it would deprive a large number of women of the
safest method of contraception because a growing num-
ber of genetic risk factors for venous thrombosis have
been discovered. Moreover, it would prevent only a small
number of deaths due to pulmonary emboli.164 Finally,
it would imply population genetic screening, which has
many ethical and social drawbacks.165
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Assessing the family history for thrombophilic
defects in identifying women at risk of venous thrombo-
sis during OC use may be worthwhile. In some studies
the positive predictive value of a family history of throm-
bosis in a first-degree relative was rather low: 14% and
12% for women with and without previous thrombosis,
respectively,166 confirmed in a small study with a sensitiv-
ity of 16% in first and second degree family history and
11% in first degree only.167 Underestimation of the im-
portance of the family history in these studies, however,
was probably due to the selection of the subjects.168
The annual incidence of venous thromboem-
bolism in factor Vr , carriers is low
169^171 and does notLeiden
justify universal screening for this mutation.172 In case of
selective screening in high-risk patients, ethnic-specific
prevalence rates should also be taken into account in the
decision regarding screening for specific defects.173'174
Obviously, individual counseling is needed when family
members of a proband with a genetic defect ask for
screening before prescription of an OC.17S>176
Prescription
In patients with a previous venous thromboembolism,
myocardial infarction, stroke, or peripheral arterial occlu-
sive disease, OCs should not be used except for women
receiving anticoagulation therapy or having specific indi-
vidual circumstances. Because all monophasic combined
OCs are equally effective for birth control, the safest brand
should be chosen. Previous studies have shown that the
relative risk of venous thrombosis is particularly elevated
by OC use in young users and that third-generation OCs
led to higher risks of venous thrombosis than second-
generation OCs: sevenfold higher among women aged
15-19 and fourfold among women aged 20-24.32 Among
young women, venous thrombosis is more common than
arterial disease. Formulations with low-dose ethinylestra-
diol (̂  30 μg) and a second-generation (levonorgestrel)
progestagen should therefore be preferred to minimize
the risk of venous thrombosis. The effect of age should be
taken into account,177 and conventional risk factors for
cardiovascular disease should be identified in individual
women before prescription of OCs. At older ages the risk
of cardiovascular disease increases exponentially, especially
in combination with other risk factors. Therefore, women
over 35 to 40 years and women with a genetic defect
should be informed about alternative methods of contra-
ception. Before prescription of OCs special attention
should be give to conventional risk factors. Women who
refrain from smoking, who have normal blood pressure,
and who have no diabetes of hyperlipidemia have no or a
minimally increased risk of myocardial infarction regard-
less of their age. OC use should not be discouraged in all
women with familial thrombophilia, äs the risk of an un-
planned pregnancy also brings an increased risk of throm-
bosis, which may be higher than that during OC use. It is
most important to make these women aware of the possi-
ble Symptoms of a thrombotic manifestation and the
need for a diagnostic work-up in case of complaints.
CONCLUSIONS AND FUTURE
PERSPECTIVES
Multiple prospective and case-control studies have shown
that current available OCs are still associated with ve-
nous and arterial thrombosis. Venous thrombosis is a
more common disease than arterial thrombosis, espe-
cially in the younger age groups, but arterial events are
slightly more frequently lethal. The relative risk is about
fourfold increased for venous and twofold increased for
arterial thrombosis. The risk of venous thrombosis in
OC users becomes high in women with genetic risk fac-
tors for thrombosis, and the risk of arterial thrombosis
becomes high in women with classical cardiovascular
risk factors. Venous thromboembolism recurs in about a
third of surviving patients within the next decade. In
addition, in about one third of the patients venous stasis
syndrome or venous ulcers will occur within 20 years
and continue to develop even after 20 years. Improved
strategies for appropriate prophylaxis in high-risk situa-
tions and prevention of venous stasis syndrome should
be created from ongoing studies. The small but definite
increased risk of both venous and arterial thrombosis
indicates that a history of a thrombotic event is a con-
traindication to using OCs (and hormone replacement
therapy) in the future. Although the absolute risk of a
thrombotic event during OC use is low, the reduction of
known risk factors for cardiovascular disease, in particu-
lar smoking and hypertension, should be emphasized.
All patients with a previous arterial thrombotic event
should be monitored periodically by their physcian for
optimal management of conventional risk factors. Most
of the genetic defects associated with thrombosis are
still unknown, and the mechanisms by which OCs in-
duce thrombosis are poorly understood. It will be a chal-
lenge to determine these defects and to reveal the mech-
anisms in the near future.
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